Scientists have identified genetic variants in the PCSK9 gene that dramatically affect cardiovascular health and longevity. People with loss-of-function PCSK9 mutations naturally have lower LDL cholesterol and significantly reduced risk of heart disease. Conversely, gain-of-function mutations cause familial hypercholesterolemia, leading to early cardiovascular events. This research has led to breakthrough PCSK9 inhibitor drugs that mimic the protective genetic variants. The findings suggest that targeting PCSK9 through medications or lifestyle interventions could be a powerful strategy for extending healthspan by preventing cardiovascular disease, one of the leading causes of premature death.
